{"contentid": 487990, "importid": NaN, "name": "Orionis in drug discovery tie-up with MD Anderson", "introduction": "Orionis Biosciences, a privately-held genome-scale drug discovery company, and The University of Texas MD Anderson Cancer Center\u00e2\u0080\u0099s Therapeutics Discovery division, have announced the launch of a research collaboration.", "content": "<p>Orionis Biosciences, a privately-held genome-scale drug discovery company, and The University of Texas MD Anderson Cancer Center&rsquo;s Therapeutics Discovery division, have announced the launch of a research collaboration.</p>\n<p>Project Helios is designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.</p>\n<p><span class=\"pullQuote\">\"A fundamental step toward new approaches in drug discovery that will enlighten our understanding of the dark proteome\"</span>By combining Orionis&rsquo; high-throughput drug discovery technologies with the Therapeutics Discovery division&rsquo;s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing.</p>\n<p>The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.</p>\n<p>Niko Kley, chief executive officer at Boston-based Orionis, said: &ldquo;We are excited to be collaborating with MD Anderson&rsquo;s Therapeutics Discovery team in launching Project Helios, a fundamental step toward new approaches in drug discovery that will enlighten our understanding of the dark proteome.</p>\n<p>&ldquo;This effort will build on a wealth of public data, chemical and clinical knowledge that has been assembled over many years across the pharmaceutical industry and biomedical institutions.&rdquo;</p>\n<h2>'New level of detail'</h2>\n<p>Molecular interactions between small-molecule drugs and proteins define both their therapeutic efficacy as well as undesired adverse effects. A comprehensive unraveling of these interactions is fundamentally important both for illuminating new drug development opportunities and devising safer medicines with fewer related toxicities.</p>\n<p>Philip Jones, vice president of Therapeutics Discovery at MD Anderson, said: &ldquo;We are pleased to be collaborating with Orionis on this exciting initiative to understand drug-target interactions at a new level of detail.</p>\n<p>&ldquo;The intersection of the data from Project Helios with the unparalleled translational research and drug discovery capabilities at MD Anderson should yield important insights for therapeutics development, hopefully resulting in impactful new medicines for patients with cancer.&rdquo;</p>\n<h2>Multiple opportunities</h2>\n<p>Project Helios will conduct systematic and unbiased mapping of drug interactions across the human proteome with a large portfolio of bioactive, chemically diverse small molecules, including experimental and approved drugs.</p>\n<p>The findings may provide opportunities to repurpose approved therapies, optimize therapeutic approaches for known targets and develop therapies for new targets.</p>", "date": "2021-03-09 16:54:00", "meta_title": NaN, "meta_keywords": "discovery, drug, Orionis, Anderson, therapeutics, project, Helios, genome-scale, interactions, research, cancer, therapies, proteome, approaches, tie-up", "meta_description": "Orionis Biosciences, a privately-held genome-scale drug discovery company, and The University of Texas MD Anderson Cancer Center\u00e2\u0080\u0099s Therapeutics Discovery divisi", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-09 15:55:20", "updated": "2021-03-09 16:54:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/orionis-in-drug-discovery-tie-up-with-md-anderson", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "orionis_biosciences_large-1-.png", "image2id": "orionis_biosciences_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Deals, Research", "geography_tag": "USA", "company_tag": "Orionis Biosciences, The University of Texas MD Anderson Cancer Center", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-09 16:54:00"}